AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9690726 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 3 mg/60 mL enema (BDP)
Number of subjects: 157
Study 9690726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone sodium phosphate 30 mg/60 mL enema (PP)
Number of subjects: 157
Study 7916398 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 24
Study 7916398 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 24
Study 7916398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Enteral feeding and Total parenteral nutrition)
Number of subjects: 24
Study 2627930 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and sanitation intervention (provision of handpumps, construction of latrines, hygiene education)
Number of subjects: 200
Study 2627930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 29938557 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-focused cognitive group therapy (11 sessions)
Number of subjects: 42
Study 29938557 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (no immediate treatment)
Number of subjects: 42
Study 25157500 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression care
Number of subjects: 0
Study 25157500 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23257208 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided, intensive patient management (BMC)
Number of subjects: 0
Study 23257208 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary care (MC)
Number of subjects: 0
Study 23257208 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 21502567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (5 pmol/kg per minute for 1 hour)
Number of subjects: 26
Study 21502567 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 26
Study 18931204 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Human Albumin (HA), n = 25
Number of subjects: 50
Study 18931204 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (6% HES 130/0.4), n = 25
Number of subjects: 50
Study 18931204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HA and HES)
Number of subjects: 50
Study 16595219 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and intrauterine insemination (IUI)
Number of subjects: 135
Study 16595219 — intervention group
Group type: COMPARATOR
Intervention: luteal phase down‐regulation with LA, hMG, and IUI
Number of subjects: 135
Study 16595219 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and IUI
Number of subjects: 135
Study 12826159 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 86
Study 12826159 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant therapy
Number of subjects: 86
Study 10702883 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cilostazol suspension
Number of subjects: 0
Study 10702883 — intervention group
Group type: COMPARATOR
Intervention: 100 mg cilostazol tablet
Number of subjects: 0
Study 10702883 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg cilostazol ethanolic solution
Number of subjects: 0
Study 10702883 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal with 100 mg cilostazol
Number of subjects: 0
Study 8726790 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg daily)
Number of subjects: 71
Study 8726790 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (50 to 150 mg daily)
Number of subjects: 71
Study 1945512 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative venogram
Number of subjects: 0
Study 1945512 — intervention group
Group type: COMPARATOR
Intervention: No preoperative venogram
Number of subjects: 0
Study 7067470 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (SC) treatment with extensive efforts to reduce barriers to care
Number of subjects: 10940
Study 7067470 — intervention group
Group type: COMPARATOR
Intervention: Referral to community sources for care (RC)
Number of subjects: 10940
Study 7067470 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level as a predictor of drug adherence
Number of subjects: 10940
Study 7067470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill counts
Number of subjects: 10940
Study 29212345 — intervention group
Group type: EXPERIMENTAL
Intervention: iOS-based app with transmitter/disposable sensor and manualized intervention
Number of subjects: 33
Study 29212345 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment
Number of subjects: 33
Study 29322810 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 23
Study 26544859 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual walking treatment
Number of subjects: 44
Study 24569459 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN23 (0.003-0.3 mg/kg i.v. or 0.1-1 mg/kg s.c.)
Number of subjects: 38
Study 24569459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25780646 — intervention group
Group type: EXPERIMENTAL
Intervention: Chukyu (spine-healing) pharmacopuncture
Number of subjects: 45
Study 25780646 — intervention group
Group type: COMPARATOR
Intervention: Normal saline pharmacopuncture
Number of subjects: 45
Study 19046855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 2.5 mg
Number of subjects: 17
Study 19046855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 5.0 mg
Number of subjects: 17
Study 19046855 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam 2.5 mg
Number of subjects: 17
Study 19046855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (both doses)
Number of subjects: 17
Study 19046855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscopy
Number of subjects: 17
Study 18086982 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized attention from a massage therapist (20 minutes)
Number of subjects: 605
Study 18086982 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage by a massage therapist each evening for up to 5 postoperative days
Number of subjects: 605
Study 18086982 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 605
Study 14720531 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 400mg BD for 2 weeks prior to DCCV and 200mg daily for 8 weeks followed by placebo for 44 weeks
Number of subjects: 161
Study 14720531 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 400mg BD for 2 weeks then 200mg daily for 52 weeks
Number of subjects: 161
Study 14720531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 11153968 — intervention group
Group type: EXPERIMENTAL
Intervention: Actor version of the Symptom Interpretation Scale (SIS)
Number of subjects: 0
Study 11153968 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer version of the Symptom Interpretation Scale (SIS)
Number of subjects: 0
Study 9227184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 200
Study 9227184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorabid
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Keflex
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprax
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceclor
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefzil
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vantin
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Cillin-K
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Veetids
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfatrim
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediazole
Number of subjects: 12
Study 8190556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynapen
Number of subjects: 12
Study 3069476 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (n = 11)
Number of subjects: 23
Study 3069476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 23
Study 26588940 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 103
Study 26588940 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 103
Study 28242632 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m2 intravenously on days 1 and 8
Number of subjects: 452
Study 28242632 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine 850, 1,000, or 1,200 mg/m2 intravenously on day 1 of a 21-day cycle
Number of subjects: 452
Study 28242632 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (in liposarcoma subgroup)
Number of subjects: 452
Study 28242632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 452
Study 25831464 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 89
Study 25831464 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 89
Study 25831464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 89
Study 25831464 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 89
Study 25831464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir
Number of subjects: 89
Study 25831464 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 89
Study 23255536 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reporting arm
Number of subjects: 1502
Study 23255536 — intervention group
Group type: COMPARATOR
Intervention: Delayed reporting arm
Number of subjects: 1502
Study 23255536 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 1502
Study 21094951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 102
Study 21094951 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 102
Study 19186315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (adjustable to 25 mg or 100 mg based on patient response)
Number of subjects: 129
Study 19186315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 16760504 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (500-1,500 microg/day) plus oral iron
Number of subjects: 1035
Study 16760504 — intervention group
Group type: COMPARATOR
Intervention: Oral iron alone
Number of subjects: 1035
Study 14985229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (50 g/m² body surface)
Number of subjects: 6
Study 14985229 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (37.5 g/m²)
Number of subjects: 6
Study 14985229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat and glucose (mixed test)
Number of subjects: 6
Study 14985229 — intervention group
Group type: COMPARATOR
Intervention: Water (control test)
Number of subjects: 6
Study 11301639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea water
Number of subjects: 0
Study 11301639 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mM NaCl
Number of subjects: 0
Study 11301639 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM KCl
Number of subjects: 0
Study 11301639 — intervention group
Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 0
Study 9266794 — intervention group
Group type: EXPERIMENTAL
Intervention: 6F guiding catheter
Number of subjects: 460
Study 9266794 — intervention group
Group type: COMPARATOR
Intervention: 7F or 8F guiding catheter
Number of subjects: 460
Study 8499958 — intervention group
Group type: EXPERIMENTAL
Intervention: Systen (3.2 mg micronized 17 beta-estradiol transdermal patch)
Number of subjects: 745
Study 8499958 — intervention group
Group type: COMPARATOR
Intervention: Estraderm (older transdermal therapeutic system)
Number of subjects: 745
Study 3544753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (group B)
Number of subjects: 54
Study 3544753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (group D)
Number of subjects: 54
Study 3544753 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 54
Study 3544753 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 54
Study 2600130 — intervention group
Group type: EXPERIMENTAL
Intervention: St Jude Medical (SJM) prosthesis
Number of subjects: 357
Study 2600130 — intervention group
Group type: COMPARATOR
Intervention: Björk-Shiley valve (BSM) and Starr-Edwards 6120 valve prosthesis
Number of subjects: 357
Study 31409691 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice exposure during the first or second 6 hours of polysomnography
Number of subjects: 47
Study 31409691 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice exposure
Number of subjects: 47
Study 27810126 — intervention group
Group type: EXPERIMENTAL
Intervention: Juzen-taiho-to (JTT) 0.10-0.25g/kg/day
Number of subjects: 0
Study 27810126 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 0
Study 27810126 — intervention group
Group type: EXPERIMENTAL
Intervention: Juzen-taiho-to (JTT)
Number of subjects: 0
Study 25248648 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (8 ml h(‐1))
Number of subjects: 24
Study 25248648 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine (2 ml h(‐1))
Number of subjects: 24
Study 25248648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both concentrations (0.1% and 0.4%)
Number of subjects: 24
Study 23895863 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-port transumbilical endoscopic cholecystectomy (group A)
Number of subjects: 32
Study 23895863 — intervention group
Group type: COMPARATOR
Intervention: Conventional 4-port routine endoscopic cholecystectomy (group B)
Number of subjects: 32
Study 21490141 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game play
Number of subjects: 22
Study 21490141 — intervention group
Group type: COMPARATOR
Intervention: Rest in a sitting position
Number of subjects: 22
Study 19398603 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 11
Study 19398603 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 11
Study 19398603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 11
Study 16621438 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% CO2 challenge
Number of subjects: 473
Study 16621438 — intervention group
Group type: COMPARATOR
Intervention: Room air control
Number of subjects: 473
Study 15342297 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients presenting during peak hours (Monday to Friday 8a.m. to 8 p.m., n = 1,047)
Number of subjects: 2082
Study 15342297 — intervention group
Group type: COMPARATOR
Intervention: Patients presenting during off-peak hours (weeknights from 8 p.m. to 8 a.m. and weekends, n = 989)
Number of subjects: 2082
Study 11331717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (home visitation every other week for 1 year)
Number of subjects: 181
Study 11331717 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 181
Study 11331717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 181
Study 11331717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study 9232342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid
Number of subjects: 228
Study 9232342 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of ascorbic acid
Number of subjects: 228
Study 9232342 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of ascorbic acid
Number of subjects: 228
Study 9232342 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 228
Study 8489978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous droperidol (2.5 mg)
Number of subjects: 107
Study 8489978 — intervention group
Group type: COMPARATOR
Intervention: Control (no droperidol)
Number of subjects: 107
Study 3501274 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha (5.5 megaunits/m2 body surface daily for 21 days, then twice a week for six months)
Number of subjects: 20
Study 3501274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 30698538 — intervention group
Group type: EXPERIMENTAL
Intervention: Early seizures (occurred from 1 to 7 days after TBI)
Number of subjects: 237
Study 30698538 — intervention group
Group type: EXPERIMENTAL
Intervention: Late seizures (occurred later than 7 days after TBI)
Number of subjects: 237
Study 30698538 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TBI in patients with early seizures
Number of subjects: 237
Study 30698538 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of early and late PTS
Number of subjects: 237
Study 30698538 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of posttraumatic epilepsy (PTE)
Number of subjects: 237
Study 27036113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (specific macronutrient content not detailed)
Number of subjects: 111
Study 23131287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenxia Sijunzi decoction
Number of subjects: 80
Study 23131287 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (multienzyme tablets and mosapride dispersible tablets)
Number of subjects: 80
Study 23131287 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine symptomatic treatment)
Number of subjects: 80
Study 21157174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement group training program (10 sessions, once a week for 10 weeks)
Number of subjects: 87
Study 17993948 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe head trauma who became brain dead
Number of subjects: 388
Study 17993948 — intervention group
Group type: COMPARATOR
Intervention: Various therapies to maintain hemodynamic stability for organ donation
Number of subjects: 388
Study 15884097 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention designed to improve mammography screening
Number of subjects: 897
Study 12206622 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 units/kg body weight
Number of subjects: 48
Study 12206622 — intervention group
Group type: COMPARATOR
Intervention: 8 units/kg body weight
Number of subjects: 48
Study 9927272 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 350
Study 8548117 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining sinus rhythm through chronic administration of antiarrhythmic agents
Number of subjects: 0
Study 8548117 — intervention group
Group type: COMPARATOR
Intervention: Controlling ventricular rate and chronic anticoagulation
Number of subjects: 0
Study 1963022 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 60 mg
Number of subjects: 892
Study 1963022 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 892
Study 1963022 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 892
Study 1963022 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 IU tds
Number of subjects: 892
Study 7221357 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g of bacampicillin plus 1.0 g of probenecid
Number of subjects: 228
Study 7221357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g of bacampicillin plus 1.0 g of probenecid
Number of subjects: 228
Study 7221357 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g of ampicillin plus 1.0 g of probenecid
Number of subjects: 228
Study 31331240 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for postoperative care (4- to 6-day intubation, determined choice, dosage, and duration of sedating medications)
Number of subjects: 16
Study 31331240 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for postoperative care
Number of subjects: 16
Study 31331240 — intervention group
Group type: COMPARATOR
Intervention: Preprotocol management (case-by-case)
Number of subjects: 16
Study 30012355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral cholecalciferol (100,000 IU vitamin D3 at baseline and week 2)
Number of subjects: 330
Study 30012355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 26184499 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-Together intervention
Number of subjects: 42
Study 26184499 — intervention group
Group type: COMPARATOR
Intervention: Minimal Ethical Care (MEC)
Number of subjects: 42
Study 26184499 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-Together
Number of subjects: 42
Study 24169195 — intervention group
Group type: COMPARATOR
Intervention: Mesh plug repair
Number of subjects: 594
Study 24169195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein's operation
Number of subjects: 594
Study 22687487 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy plus placebo
Number of subjects: 663
Study 22687487 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR + escitalopram
Number of subjects: 663
Study 22687487 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR + mirtazapine
Number of subjects: 663
Study 22687487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatments (bupropion SR + escitalopram or venlafaxine XR + mirtazapine)
Number of subjects: 663
Study 22687487 — intervention group
Group type: COMPARATOR
Intervention: SSRI monotherapy
Number of subjects: 663
Study 19625712 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose peginterferon alfa‐2b (1.5 microg/kg/week) + ribavirin (800-1400 mg/day)
Number of subjects: 3070